The GENFI investigators have a number of ongoing projects which are aiming to develop new biomarkers for genetic FTD.


We are working on an extension of the Clinical Dementia Rating scale as well as new symptom scales.


We are developing novel ways to assess cognition in genetic FTD, including developing composite scores and computerized batteries.


We are working on new ways of analysing all of our different MR imaging methods including the application of machine learning methodologies.


We are developing new fluid biomarkers of neuronal and glial damage as well as markers of inflammation, and both synaptic and lysosomal dysfunction.


The GENFI cohort has been genotyped and we are looking at genetic modifiers of phenotype and the relationship with imaging.